- Fox Foundation to sponsor a clinical trial to study Sanofi compound -
PARIS, France, April 19, 2012 /CNW Telbec/ - Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor - phosphodiesterase type 4 inhibitor - in patients with Parkinson's disease (PD).
"AVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease, an area of unmet need where a new treatment could make a tangible difference in patients' lives," said Todd Sherer, Ph.D., Chief Executive Officer of MJFF. "Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation's approach and help us speed scientific advances with potential to improve the treatment of Parkinson's for patients today and in the future."
Under the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinson's disease. All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. Further development plans will be based upon the results of the study.
"The Michael J. Fox Foundation has been a driving force in discovering and developing improved therapies for those living with Parkinson's disease. Through this research collaboration, together we will be able to study Sanofi's pharmaceutical compound for a possible new treatment for PD patients around the world," said Dr. Elias Zerhouni, President, Global R&D, Sanofi. "We hope to continue to develop relationships with private foundations like the Michael J. Fox Foundation to pool our resources and maximize the potential of our drug portfolio to address unmet medical needs."
The clinical trial will be conducted at clinical sites in the United States in Baltimore, MD, and Los Angeles, CA. Patient enrollment in the study is expected to begin later this year.
***
About Parkinson's Disease
Over one million people in the US and an estimated 5 million people
globally suffer from Parkinson's disease, a neurodegenerative disorder
caused by the diminished production of dopamine, a key
neurotransmitter, resulting in progressive impairment of motor function
including tremors, rigidity and difficulty in moving. Another symptom
of PD is cognitive dysfunction, such as difficulty planning,
sequencing, initiating and sustaining behavior toward a goal. Estimates
vary but some studies suggest a cognitive deficit may occur in up to
80% of people with Parkinson's. While there is a drug approved for the
treatment of dementia in PD, there are currently no treatments
available for patients who experience less severe cognitive
impairments.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest private funder of Parkinson's research, The
Michael J. Fox Foundation is dedicated to accelerating a cure for
Parkinson's disease and improved therapies for those living with the
condition today. The Foundation pursues its goals through an
aggressively funded, highly targeted research program coupled with
active global engagement of scientists, Parkinson's patients, business
leaders, clinical trial participants, donors and volunteers. In
addition to funding more than $285 million in research to date, the
Foundation has fundamentally altered the trajectory of progress toward
a cure. Operating at the hub of worldwide Parkinson's research, the
Foundation forges groundbreaking collaborations with industry leaders,
academic scientists and government research funders; increases the flow
of participants into Parkinson's disease clinical trials with its
online tool, Fox Trial Finder; promotes Parkinson's awareness through
high-profile advocacy, events and outreach; and coordinates the
grassroots involvement of thousands of Team Fox members around the
world. Now through December 31, 2012, all new and increased giving to
The Michael J. Fox Foundation, as well as gifts from donors who have
not given since 2009 or earlier, will be matched on a dollar-for-dollar
basis with the $50-million Brin Wojcicki Challenge, launched by Sergey
Brin and Anne Wojcicki.
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied
or projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory
authorities, such as the FDA or the EMA, regarding whether and when to
approve any drug, device or biological application that may be filed
for any such product candidates as well as their decisions regarding
labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates,
the impact of cost containment policies and subsequent changes thereto,
the average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to
update or revise any forward-looking information or statements.
Sanofi Corporate Media Relations
Marisol Péron
Tel: +33 (0) 1 53 77 45 02
Mobile: +33 (0) 6 08 18 94 78
E-mail: marisol.peron@sanofi.com
Michael J. Fox Foundation
Jena Levy
Tel: (212) 509-0995 x294
E-mail: jlevy@michaeljfox.org
Sanofi North America - R&D Communications
Elizabeth Baxter
Tel: (908) 981-5360
E-mail: elizabeth.baxter@sanofi.com